by Katie Porter | Aug 22, 2017 | Blog, EpiVax Immunoncology, Featured, News
EpiVax has carved out a niche in the biotech and immunoinformatics industry with our innovative tools and discoveries. Well-situated on a trajectory Dr. De Groot described as “upward and stable,” EpiVax is now gearing up to launch a venture-backed spinoff called...
by Annie De Groot | May 24, 2017 | Blog, Featured, News
A new article in Nature Scientific Reports (doi: 10.1038/s41598-017-01372-5) entitled A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines may explain why H7N9 influenza vaccines are consistently less immunogenic in humans than...
by Katie Porter | May 18, 2017 | Blog, Featured, News
Nineteen years ago, on May 18th, 1998, EpiVax incorporated as a biotechnology company. In 2017, our business has never been stronger: the team is stacked with talent, collaborations are abundant and world-wide, and our in silico user base is extensive. We were...
by Steven Vessella | Apr 25, 2017 | Blog, Featured, News
EpiVax Signs First Commercial License for Tregitope Technology PROVIDENCE, R.I., April 25, 2017 – Providence-based biotechnology company EpiVax, Inc. (“EpiVax”) has licensed its novel immune-modulating technology to an undisclosed global...
by Katie Porter | Apr 14, 2017 | Events, Featured
Those of us on the U.S. East Coast are happy to say farewell to winter – Spring is Here! And EpiVax is springing up everywhere! Join us at the following events to learn more about immunogenicity, influenza vaccines, personalized cancer vaccines and more!...
by Annie De Groot | Mar 7, 2017 | Blog, Featured, News
“Insanity: doing the same thing over and over again and expecting different results.” – Albert Einstein. Due to its high rate of lethality (30-40%) and pandemic potential, H7N9 preparedness has become a priority for public health officials. While...
